Companies Bicara Therapeutics Inc.
Bicara Therapeutics (BCAX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Bicara Therapeutics Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $8,918,523FY2024
- $927,688FY2025
CEO total pay was $927,688 in fiscal 2025, down from $8,918,523 in fiscal 2024.
FY2025: salary $625,000 · bonus $0 · stock awards $0 · option awards $0
Order BCAX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Claire Mazumdar | $625,000 | $0 | $0 | $0 | $292,188 | $0 | $10,500 | $927,688 |
| Chief Executive Officer | ||||||||
| Ryan Cohlhepp | 588,000 | 10,000 | 0 | 0 | 249,900 | 0 | 10,500 | 858,400 |
| President and Chief Operating Officer | ||||||||
| David Raben | 525,000 | 5,000 | 0 | 0 | 170,625 | 0 | 8,539 | 709,164 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Claire Mazumdar | $927,688 | $8,918,523 | — | ↓ −7,990,835 |
| Ryan Cohlhepp | 858,400 | 4,467,589 | — | ↓ −3,609,189 |
| David Raben | 709,164 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company's compensation philosophy is designed to motivate employees to achieve short- and long-term results in the best interests of stockholders, aligning executive interests with stockholders through equity grants that create an ownership culture and promote retention. Compensation is set based on market benchmarks, individual performance, and a desire to maintain a competitive position.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Claire Mazumdar | Option | 3,126 | 4.1 | — |
| Claire Mazumdar | Option | 8,334 | 4.1 | — |
| Claire Mazumdar | Option | 16,227 | 4.44 | — |
| Claire Mazumdar | Option | 17,710 | 4.1 | — |
| David Raben | Option | 37,863 | 3.79 | — |
| Claire Mazumdar | Option | 44,625 | 3.79 | — |
| David Raben | Option | 66,004 | 3.79 | — |
| Claire Mazumdar | Option | 68,965 | 3.79 | — |
| David Raben | Option | 77,080 | 5.45 | — |
| Claire Mazumdar | Option | 90,981 | 4.1 | — |
| Claire Mazumdar | Option | 106,254 | 3.79 | — |
| David Raben | Option | 148,753 | 9.24 | — |
| Claire Mazumdar | Option | 163,050 | 3.79 | — |
| Claire Mazumdar | Option | 189,320 | 5.45 | — |
| Claire Mazumdar | Option | 297,504 | 5.45 | — |
| Claire Mazumdar | Option | 353,287 | 9.24 | — |
| Claire Mazumdar | Option | 784,672 | 9.24 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael PowellIndependent | $87,500 | — | $208,634 | — | — | $296,134 |
| Scott RobertsonIndependent | 55,000 | — | 208,634 | — | — | 263,634 |
| Nils LonbergIndependent | 48,000 | — | 208,634 | — | — | 256,634 |
| Christopher BowdenIndependent | 45,000 | — | 208,634 | — | — | 253,634 |
| Kate HavilandIndependent | 45,000 | — | 208,634 | — | — | 253,634 |
| Jake SimsonIndependent | 44,000 | — | 208,634 | — | — | 252,634 |
| Kiran Mazumdar-ShawIndependent | 44,000 | — | 208,634 | — | — | 252,634 |
| Carolyn NgIndependent | 0 | — | 0 | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $47,492 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $368,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $368,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Bicara Therapeutics as a peer
Companies that benchmark against BCAX
No companies currently name BCAX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics Inc. | 2025 | Claire Mazumdar | $625,000 | $0 | $0 | $292,188 | $927,688 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | — | — | — | — | — |
| 2025 | 2025-06-09 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | —a |
| 2025 | 2025-06-09 | —b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Claire Mazumdar. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 927,688. View filing ↗
- Section 01, Ryan Cohlhepp. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 858,400. View filing ↗
- Section 01, David Raben. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 709,164. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-30. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Michael Powell. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 296,134. View filing ↗
- Section 08, Scott Robertson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 263,634. View filing ↗
- Section 08, Nils Lonberg. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 256,634. View filing ↗
- Section 08, Christopher Bowden. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 253,634. View filing ↗
- Section 08, Kate Haviland. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 253,634. View filing ↗
- Section 08, Jake Simson. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 252,634. View filing ↗
- Section 08, Kiran Mazumdar-Shaw. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 252,634. View filing ↗
- Section 08, Carolyn Ng. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-12. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 368,500 + equity 0 + all other 0 = 368,500, summed across the director compensation table rows.
- Bicara Therapeutics Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Bicara Therapeutics Inc.'s own proxy. As printed: 927,688. View filing ↗